Hashemi Seyed Basir, Monshizadeh Leila, Kazemi Tayebeh, Cheraghzadeh Seyed Reza, Malek-Hosseini Seyed Ali
Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Otorhinolaryngol. 2024;36(6):663-667. doi: 10.22038/ijorl.2024.76676.3571.
As far as it is known, long-lasting immunosuppressive therapy might put patients with solid organ transplantation (SOT) at increased risk for severe to profound sensorineural hearing loss, eventually leading to cochlear implantation (C.I). So, the main aim of the present study is to evaluate their auditory perception performance after cochlear implantation.
This case-series study assessed the auditory perception performance of our center's six cochlear-implanted patients who had undergone solid organ transplantation before. The patients' age range was between 3 to 68 years old. Two participants (Female/ male) had received liver transplantation, and the rest (two males and two females) had undergone kidney transplantation. The assessment was conducted through the CAP (Categories of Auditory Performance) test in the first month of cochlear implantation and 12 months later.
Except for one patient (A 3-year-old girl) who has recently received a cochlear implantation device, and her rehabilitation program is in progress, the auditory perception performance of others improved from 2 to at least six scores. Also, no wound infection, mastoiditis, or bacterial meningitis occurred after cochlear implantation.
Immunosuppressive therapy, hemodialysis, infections, and long-lasting medication might lead to severe to profound sensory neural hearing loss in organ-transplanted patients. In recent years, cochlear implantation has been considered a final solution to help this group of patients to hear and communicate better.
据了解，长期免疫抑制治疗可能会使实体器官移植（SOT）患者出现严重至极重度感音神经性听力损失的风险增加，最终导致需要进行人工耳蜗植入（C.I）。因此，本研究的主要目的是评估他们在人工耳蜗植入后的听觉感知表现。
本病例系列研究评估了我们中心6例之前接受过实体器官移植的人工耳蜗植入患者的听觉感知表现。患者年龄在3至68岁之间。两名参与者（女性/男性）接受了肝移植，其余（两男两女）接受了肾移植。评估在人工耳蜗植入后的第一个月和12个月后通过听觉表现类别（CAP）测试进行。
除了一名最近接受人工耳蜗植入设备的患者（一名3岁女孩），其康复计划正在进行中，其他患者的听觉感知表现从2分提高到至少6分。此外，人工耳蜗植入后未发生伤口感染、乳突炎或细菌性脑膜炎。
免疫抑制治疗、血液透析、感染和长期用药可能导致器官移植患者出现严重至极重度感音神经性听力损失。近年来，人工耳蜗植入已被视为帮助这组患者更好地听力和交流的最终解决方案。
